Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Forsteo Summary of Product Characteristics (SmPC)

Forsteo® (Teriparatide): Repeating the 24-month course of treatment

The maximum total duration of treatment with Forsteo should be 24 months. The 24-month course of Forsteo should not be repeated over a patient’s lifetime.

Further Information from Summary of Product Characteristics

Studies in rats indicate an increased incidence of osteosarcoma with long-term administration of teriparatide. Until further clinical data become available, the recommended treatment time of 24 months should not be exceeded.1

Following cessation of Forsteo therapy, patients may be continued on other osteoporosis therapies.1


1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: March 03, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request